In this, the second of three videos in which Sunita Nasta, MD, FACP reviews findings from ASH on the aggressive lymphomas, Dr. Nasta considers diffuse large B cell lymphomas (DLBCL). Among other advances, her presentation includes an overview of current investigational targeted therapies and a consideration of RCHOP therapies, as well as the introduction of two agents, a novel, oral dual inhibitor of histone deacetylas and P13K and venetoclax monotherapy, for patients with relapsed/refractory DLBCL.
To view other parts of this program:
Related Links
Published
December 7, 2016
Created by
BROADCASTMED